249 related articles for article (PubMed ID: 30910600)
1. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
[TBL] [Abstract][Full Text] [Related]
2. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
3. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
[TBL] [Abstract][Full Text] [Related]
4. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
[TBL] [Abstract][Full Text] [Related]
5. The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.
Makras P; Yavropoulou MP; Polyzos SA; Papapoulos SE; Georgakopoulou D; Papatheodorou A; Anastasilakis AD
Osteoporos Int; 2024 Feb; 35(2):365-370. PubMed ID: 37783758
[TBL] [Abstract][Full Text] [Related]
6. Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.
Tsourdi E; Makras P; Rachner TD; Polyzos S; Rauner M; Mandanas S; Hofbauer LC; Anastasilakis AD
Bone; 2019 Mar; 120():44-49. PubMed ID: 30292818
[TBL] [Abstract][Full Text] [Related]
7. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
8. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
9. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
10. Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison's disease.
Furman K; Gut P; Sowińska A; Ruchała M; Fichna M
Endocrine; 2024 May; 84(2):711-719. PubMed ID: 38334892
[TBL] [Abstract][Full Text] [Related]
11. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
[TBL] [Abstract][Full Text] [Related]
12. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
[TBL] [Abstract][Full Text] [Related]
13. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
Uebelhart B; Rizzoli R; Ferrari SL
Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
Hong N; Shin S; Lee S; Kim KJ; Rhee Y
Calcif Tissue Int; 2022 Jul; 111(1):47-55. PubMed ID: 35226133
[TBL] [Abstract][Full Text] [Related]
17. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
18. Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.
Peng J; Dong Z; Hui Z; Aifei W; Lianfu D; Youjia X
BMC Musculoskelet Disord; 2021 May; 22(1):480. PubMed ID: 34034718
[TBL] [Abstract][Full Text] [Related]
19. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
[TBL] [Abstract][Full Text] [Related]
20. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
Miller PD; Bolognese MA; Lewiecki EM; McClung MR; Ding B; Austin M; Liu Y; San Martin J
Bone; 2008 Aug; 43(2):222-229. PubMed ID: 18539106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
